Day 1 - 5 January (9:00 - 18:00):

**9:00 - 9:15**  
**Opening Session** - Prof. Sir John Bell (Regius Professor of Medicine, University of Oxford)

**9:15 - 10:00**  
**Plenary** – Dr. Patrick Vallance (Senior Vice-President, Medicines Discovery and Development, GSK)  
"Making Medicines"

**10:00 - 10:30**  
Coffee break

**10:30 - 12:30**  
**Session 1: How do we better select targets for Drug Discovery?**  
**Chairs:**  
Dr. Rab Prinjha (Director, Head of Target Progression, GSK)  
Prof. Peter Ratcliffe (Head of the Nuffield Dept of Clinical Medicine, University of Oxford)  
**Panellists:**  
Dr. Lorenz Mayr (Executive Director, Unit Head Biology, Protease Platform, Novartis)  
"Target Validation Strategies for Proteases"  
Dr. Huseyin Mehmet (Head of target identification and validation, Merck)  
"TBC"  
Dr. Jane Hughes (Associate Director, Neuroscience, MedImmune)  
"The use of Biologics to aid Target Identification and Validation"

**12:30 - 13:30**  
Lunch break

**13:30 - 15:30**  
**Session 2: What are the limitations of single molecule targets?**  
**Chairs:**  
Prof. Julian Blagg (Prof. Medicinal Chemistry, Institute of Cancer Research, UK)  
Dr. Anne Phelan (Executive Director & Head of the Research Enabling Group, Pfizer)  
**Panellists:**  
Prof. Andrew Hopkins (Professor of Medicinal Informatics, University of Dundee)  
"Expanding Opportunity Space with Polypharmacology"  
Dr. John Overington (Team Leader, Computational Chemical Biology, EMBL-EBI)  
"The Benefits of Open Data in Drug Discovery"  
Dr. Alan D Brown (Head of Chemistry, Pfizer Neusentis)  
"What are the limitations of single molecule targets? Some dogmatism based on bitter experience..."

**15:30 - 16:00**  
Coffee break

**16:00 - 18:00**  
**Session 3: How useful are animal models in Drug Discovery?**  
**Chairs:**  
Dr. Paul Chapman (General Manager, Pharmaceutical Research Division, Takeda)  
Dr. Theo Meert (Senior Director, External Innovation Neurosciences, Janssen R&D)  
**Panellists:**  
Dr. Gerry Dawson (Chief Scientist, P1vital, UK)  
"From animal models of psychiatric diseases to humans – why so difficult?"  
Dr. Robert Coleman (Independent Consultant)  
"Human Questions Call for Human Answers: focussing on the relevant"  
Dr. Nico Scheer (Head of ADMET Research, Taconic Artemis)  
"The use of humanized animal models in testing the ADMET characteristics of new compounds in vivo."
# Drug Discovery: a job too complex for academia or industry alone?

**University of Oxford • 5th – 6th January 2012**

www.thescgc.org/DDOx2012 • thesgconline #DDOx2012

## Day 2 - 6 January (9:00 - 16:30):

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 4: What is limiting Drug Discovery in Academia?</th>
</tr>
</thead>
</table>
| 9:00 - 11:00  | Chairs: Prof. Andy Hamilton (Vice-Chancellor, University of Oxford)  
Dr. Andy Takle (Director of Translational Research, Cancer Research UK) |
|               | Panellists: Dr. Dave Tapolczay (Chief Executive, MRC Technology)  
"The role of Public/Private partnerships in Drug Discovery: A new business model for Pharmaceutical R&D"  
Prof. Herbie Newell (Professor of Cancer Therapeutics, University of Newcastle)  
"Discovering targeted drugs for stratified cancer medicine – targets to treatments"  
Dr. Stephen Friend (President, Sage Bionetworks)  
"TBC" |

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 5: Is there any evidence that IP in early discovery is slowing down the development of new medicines?</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 - 11:15</td>
<td>Coffee break</td>
</tr>
</tbody>
</table>
| 11:15 - 13:15 | Chairs: Prof. Aled Edwards (CEO and director, SGC)  
Dr. Malcolm Skingle (Director, External Science & Technology, GSK)  
Panellists: Dr. Monika Lesl (Head, Alliance Management Global Innovation Sourcing, Bayer Healthcare)  
"Grants4targets: an open innovation approach to foster early drug discovery"  
Prof. Alison Campbell (Managing Director, King's College London Business Ltd.)  
"Easy Access IP – the new paradigm"  
Dr. Paul FeWner (Global Head, Pharma Intellectual Property, Novartis)  
"Robust IP rights: critical to accelerating discovery, development, and access to medicine" |

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 6: What are the consequences of pharma downsizing in UK? How does UK maintain its position in Drug Discovery?</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:15 - 14:15</td>
<td>Lunch break</td>
</tr>
</tbody>
</table>
| 14:15 - 16:15 | Chairs: Dr. Phil Clare (Associate Director, Research Services, University of Oxford)  
Dr. Peter Machin (Independent)  
Panellists: Dr. Mene Pangalos (Executive Vice-President, Innovative Medicine, AstraZeneca)  
"Drug Discovery: A Job Too Complex for Academia or Industry Alone?"  
Dr. Ted Bianco (Director of Technology Transfer, The Wellcome Trust)  
"Facilitating drug discovery in an exchanging environment"  
Dr. Allan Marchington (Partner, Apposite Capital LLP)  
"Change brings opportunity - An Investors perspective" |

<table>
<thead>
<tr>
<th>Time</th>
<th>Concluding remarks, closing session – Prof. Chas Bountra (Chief Scientist, SGC Oxford)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:15 - 16:30</td>
<td></td>
</tr>
</tbody>
</table>